Cancer drug fails to show better patient survival

03/8/2005 | Reuters

Seattle-based Cell Therapeutics reported a late-stage trial failed to show its experimental lung cancer drug extended patient survival any more than standard chemotherapy. The company said the survival rate for patients with non-small cell lung cancer who received a combination of Xyotax and carboplatin was the same as patients who received paclitaxel in combination with carboplatin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA